GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Dalbavancin (Dalvance)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The U.S. label and UCSF differ in the reduced single-dose amount for CrCl <30 without regular HD (1125 mg versus 1000 mg). UCSF also includes an off-label bone/joint regimen. These are distinct versions, not matching protocols.

Check source scope before reading a dose

DALVANCE - adult ABSSSI label schedules

Product / population
Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.
Renal method
Estimated adult CrCl, mL/min; regular HD is a separate category.
Source revision
Label revised January 2025; updated 2025-01-13.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Official

DALVANCE - adult ABSSSI label schedules

Open original reference

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Estimated adult CrCl, mL/min; regular HD is a separate category.
Source date: Label revised January 2025; updated 2025-01-13.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For adult acute bacterial skin/skin-structure infection, infuse doses IV over 30 minutes.

Renal statusSingle-dose optionTwo-dose option
CrCl >=30 mL/min or regular HD1500 mg once1000 mg, then 500 mg one week later
CrCl <30 and not regular HD1125 mg once750 mg, then 375 mg one week later

Choose one regimen; do not combine them. The label's reduced single dose is 1125 mg, whereas the displayed UCSF page uses 1000 mg. UCSF's two 1500-mg osteomyelitis doses are a different off-label strategy, not this skin-infection label. Pediatric renal dosing below the studied threshold is not established.

RDM30-072-dalbavancin-1 · Source locator: DALVANCE - adult ABSSSI label schedules; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c
Retrieved
2026-09-05
DailyMed Set ID
4b4674d8-4d1e-4728-8465-d42ada33fa5c
Renal-function method
Estimated adult CrCl, mL/min; regular HD is a separate category.
Source date/version
Label revised January 2025; updated 2025-01-13.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
c0f8ea6d6ec55a44d1c7876dfa173c32742b0e7faf93b9b8df7bf2a1bebba379

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=dalbavancin&s1=RDM30-072-dalbavancin&h1=4ac9e34a3c47732bac29af38db7457958e75817c925cfec06628e6f04852cb26